patient_id,baseline_week,followup_week,V_base_ml,V_follow_ml,Delta_V_ml,Delta_V_percent,prediction,true_label,rano_rating,confidence,correct,explanation
Patient-001,week-000-1,week-044,52.17,15.82,-36.35,-69.7,Non-Progression,Non-Progression,SD,0.614,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -69.7% (baseline: 52.2 ml → follow-up: 15.8 ml). This suggests treatment response. Confidence: 61.4%.
Patient-001,week-000-1,week-056,52.17,4.68,-47.49,-91.0,Non-Progression,Progression,PD,0.659,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -91.0% (baseline: 52.2 ml → follow-up: 4.7 ml). This suggests treatment response. Confidence: 65.9%.
Patient-002,week-000,week-021,25.96,7.56,-18.4,-70.9,Non-Progression,Non-Progression,SD,0.656,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -70.9% (baseline: 26.0 ml → follow-up: 7.6 ml). This suggests treatment response. Confidence: 65.6%.
Patient-002,week-000,week-037,25.96,23.58,-2.38,-9.2,Non-Progression,Progression,PD,0.573,False,Predicted NON-PROGRESSION with tumor volume decrease of -9.2% (baseline: 26.0 ml → follow-up: 23.6 ml). Volume remains stable or reduced. Confidence: 57.3%.
Patient-002,week-000,week-047,25.96,43.52,17.56,67.6,Progression,Progression,PD,0.523,True,"Predicted PROGRESSION because tumor volume increased by 67.6% between baseline (26.0 ml) and follow-up (43.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 52.3%."
Patient-003,week-000-2,week-014,25.2,8.6,-16.6,-65.9,Non-Progression,Non-Progression,SD,0.669,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -65.9% (baseline: 25.2 ml → follow-up: 8.6 ml). This suggests treatment response. Confidence: 66.9%.
Patient-003,week-000-2,week-027,25.2,12.81,-12.39,-49.2,Non-Progression,Progression,PD,0.627,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -49.2% (baseline: 25.2 ml → follow-up: 12.8 ml). This suggests treatment response. Confidence: 62.7%.
Patient-003,week-000-2,week-038,25.2,124.08,98.88,392.3,Progression,Progression,PD,0.886,True,"Predicted PROGRESSION because tumor volume increased by 392.3% between baseline (25.2 ml) and follow-up (124.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 88.6%."
Patient-004,week-000-1,week-020,126.79,57.96,-68.83,-54.3,Progression,Progression,PD,0.636,True,Predicted PROGRESSION despite apparent volume decrease of -54.3% (baseline: 126.8 ml → follow-up: 58.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.6%. Clinical review recommended.
Patient-004,week-000-1,week-038,126.79,31.6,-95.19,-75.1,Non-Progression,Progression,PD,0.523,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -75.1% (baseline: 126.8 ml → follow-up: 31.6 ml). This suggests treatment response. Confidence: 52.3%.
Patient-004,week-000-1,week-057,126.79,63.46,-63.33,-49.9,Progression,Progression,PD,0.68,True,Predicted PROGRESSION despite apparent volume decrease of -49.9% (baseline: 126.8 ml → follow-up: 63.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 68.0%. Clinical review recommended.
Patient-004,week-000-1,week-071,126.79,41.32,-85.47,-67.4,Progression,Non-Progression,PR,0.555,False,Predicted PROGRESSION despite apparent volume decrease of -67.4% (baseline: 126.8 ml → follow-up: 41.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 55.5%. Clinical review recommended.
Patient-004,week-000-1,week-086,126.79,52.42,-74.37,-58.7,Progression,Progression,PD,0.605,True,Predicted PROGRESSION despite apparent volume decrease of -58.7% (baseline: 126.8 ml → follow-up: 52.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.5%. Clinical review recommended.
Patient-005,week-000-1,week-015,104.56,28.46,-76.1,-72.8,Non-Progression,Non-Progression,SD,0.547,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -72.8% (baseline: 104.6 ml → follow-up: 28.5 ml). This suggests treatment response. Confidence: 54.7%.
Patient-006,week-000,week-015,216.73,41.0,-175.74,-81.1,Progression,Non-Progression,SD,0.586,False,Predicted PROGRESSION despite apparent volume decrease of -81.1% (baseline: 216.7 ml → follow-up: 41.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 58.6%. Clinical review recommended.
Patient-006,week-000,week-027,216.73,47.76,-168.98,-78.0,Progression,Non-Progression,SD,0.61,False,Predicted PROGRESSION despite apparent volume decrease of -78.0% (baseline: 216.7 ml → follow-up: 47.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 61.0%. Clinical review recommended.
Patient-006,week-000,week-039,216.73,63.48,-153.25,-70.7,Progression,Non-Progression,SD,0.681,False,Predicted PROGRESSION despite apparent volume decrease of -70.7% (baseline: 216.7 ml → follow-up: 63.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 68.1%. Clinical review recommended.
Patient-006,week-000,week-053,216.73,59.64,-157.1,-72.5,Progression,Non-Progression,SD,0.622,False,Predicted PROGRESSION despite apparent volume decrease of -72.5% (baseline: 216.7 ml → follow-up: 59.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 62.2%. Clinical review recommended.
Patient-006,week-000,week-067,216.73,66.32,-150.42,-69.4,Progression,Non-Progression,SD,0.701,False,Predicted PROGRESSION despite apparent volume decrease of -69.4% (baseline: 216.7 ml → follow-up: 66.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 70.1%. Clinical review recommended.
Patient-006,week-000,week-083,216.73,69.44,-147.29,-68.0,Progression,Non-Progression,SD,0.714,False,Predicted PROGRESSION despite apparent volume decrease of -68.0% (baseline: 216.7 ml → follow-up: 69.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 71.4%. Clinical review recommended.
Patient-006,week-000,week-097,216.73,67.95,-148.78,-68.6,Progression,Progression,PD,0.699,True,Predicted PROGRESSION despite apparent volume decrease of -68.6% (baseline: 216.7 ml → follow-up: 68.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 69.9%. Clinical review recommended.
Patient-006,week-000,week-112,216.73,68.25,-148.48,-68.5,Progression,Progression,PD,0.7,True,Predicted PROGRESSION despite apparent volume decrease of -68.5% (baseline: 216.7 ml → follow-up: 68.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 70.0%. Clinical review recommended.
Patient-006,week-000,week-121,216.73,39.38,-177.36,-81.8,Progression,Non-Progression,SD,0.578,False,Predicted PROGRESSION despite apparent volume decrease of -81.8% (baseline: 216.7 ml → follow-up: 39.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 57.8%. Clinical review recommended.
Patient-006,week-000,week-131,216.73,17.05,-199.68,-92.1,Non-Progression,Progression,PD,0.574,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.1% (baseline: 216.7 ml → follow-up: 17.0 ml). This suggests treatment response. Confidence: 57.4%.
Patient-006,week-000,week-135,216.73,32.79,-183.94,-84.9,Progression,Progression,PD,0.539,True,Predicted PROGRESSION despite apparent volume decrease of -84.9% (baseline: 216.7 ml → follow-up: 32.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.9%. Clinical review recommended.
Patient-007,week-000,week-015,113.19,2.99,-110.2,-97.4,Non-Progression,Progression,PD,0.68,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -97.4% (baseline: 113.2 ml → follow-up: 3.0 ml). This suggests treatment response. Confidence: 68.0%.
Patient-007,week-000,week-028,113.19,6.58,-106.62,-94.2,Non-Progression,Progression,PD,0.663,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -94.2% (baseline: 113.2 ml → follow-up: 6.6 ml). This suggests treatment response. Confidence: 66.3%.
Patient-007,week-000,week-041,113.19,8.31,-104.89,-92.7,Non-Progression,Progression,PD,0.65,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.7% (baseline: 113.2 ml → follow-up: 8.3 ml). This suggests treatment response. Confidence: 65.0%.
Patient-007,week-000,week-055,113.19,11.1,-102.09,-90.2,Non-Progression,Progression,PD,0.654,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.2% (baseline: 113.2 ml → follow-up: 11.1 ml). This suggests treatment response. Confidence: 65.4%.
Patient-007,week-000,week-064,113.19,24.7,-88.5,-78.2,Non-Progression,Progression,PD,0.559,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.2% (baseline: 113.2 ml → follow-up: 24.7 ml). This suggests treatment response. Confidence: 55.9%.
Patient-007,week-000,week-075,113.19,46.83,-66.37,-58.6,Progression,Progression,PD,0.57,True,Predicted PROGRESSION despite apparent volume decrease of -58.6% (baseline: 113.2 ml → follow-up: 46.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 57.0%. Clinical review recommended.
Patient-007,week-000,week-089,113.19,68.55,-44.64,-39.4,Progression,Progression,PD,0.666,True,Predicted PROGRESSION despite apparent volume decrease of -39.4% (baseline: 113.2 ml → follow-up: 68.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 66.6%. Clinical review recommended.
Patient-007,week-000,week-105,113.19,50.73,-62.46,-55.2,Progression,Progression,PD,0.602,True,Predicted PROGRESSION despite apparent volume decrease of -55.2% (baseline: 113.2 ml → follow-up: 50.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.2%. Clinical review recommended.
Patient-008,week-000,week-017,117.69,19.57,-98.12,-83.4,Non-Progression,Progression,PD,0.567,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -83.4% (baseline: 117.7 ml → follow-up: 19.6 ml). This suggests treatment response. Confidence: 56.7%.
Patient-008,week-000,week-066,117.69,25.75,-91.94,-78.1,Non-Progression,Progression,PD,0.562,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.1% (baseline: 117.7 ml → follow-up: 25.8 ml). This suggests treatment response. Confidence: 56.2%.
Patient-008,week-000,week-085,117.69,23.18,-94.51,-80.3,Non-Progression,Progression,PD,0.548,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -80.3% (baseline: 117.7 ml → follow-up: 23.2 ml). This suggests treatment response. Confidence: 54.8%.
Patient-009,week-000-1,week-014,56.75,64.28,7.53,13.3,Progression,Non-Progression,SD,0.687,False,"Predicted PROGRESSION with tumor volume increase of 13.3% (baseline: 56.7 ml → follow-up: 64.3 ml). Although below the 25% heuristic threshold, the model identified progression patterns. Confidence: 68.7%."
Patient-009,week-000-1,week-024,56.75,3.39,-53.36,-94.0,Non-Progression,Non-Progression,CR,0.679,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -94.0% (baseline: 56.7 ml → follow-up: 3.4 ml). This suggests treatment response. Confidence: 67.9%.
Patient-009,week-000-1,week-066,56.75,17.64,-39.11,-68.9,Non-Progression,Progression,PD,0.614,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -68.9% (baseline: 56.7 ml → follow-up: 17.6 ml). This suggests treatment response. Confidence: 61.4%.
Patient-010,week-000,week-015,85.72,15.09,-70.63,-82.4,Non-Progression,Non-Progression,SD,0.599,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -82.4% (baseline: 85.7 ml → follow-up: 15.1 ml). This suggests treatment response. Confidence: 59.9%.
Patient-011,week-000,week-021,37.47,9.02,-28.45,-75.9,Non-Progression,Non-Progression,SD,0.665,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -75.9% (baseline: 37.5 ml → follow-up: 9.0 ml). This suggests treatment response. Confidence: 66.5%.
Patient-011,week-000,week-028,37.47,59.98,22.51,60.1,Progression,Progression,PD,0.625,True,"Predicted PROGRESSION because tumor volume increased by 60.1% between baseline (37.5 ml) and follow-up (60.0 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 62.5%."
Patient-012,week-000-1,week-016,39.09,8.56,-30.54,-78.1,Non-Progression,Non-Progression,SD,0.667,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.1% (baseline: 39.1 ml → follow-up: 8.6 ml). This suggests treatment response. Confidence: 66.7%.
Patient-012,week-000-1,week-048,39.09,49.17,10.07,25.8,Progression,Progression,PD,0.567,True,"Predicted PROGRESSION because tumor volume increased by 25.8% between baseline (39.1 ml) and follow-up (49.2 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 56.7%."
Patient-012,week-000-1,week-073,39.09,53.12,14.03,35.9,Progression,Progression,PD,0.589,True,"Predicted PROGRESSION because tumor volume increased by 35.9% between baseline (39.1 ml) and follow-up (53.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 58.9%."
Patient-012,week-000-1,week-084,39.09,64.38,25.29,64.7,Progression,Progression,PD,0.626,True,"Predicted PROGRESSION because tumor volume increased by 64.7% between baseline (39.1 ml) and follow-up (64.4 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 62.6%."
Patient-013,week-000,week-017,117.24,9.25,-107.99,-92.1,Non-Progression,Non-Progression,SD,0.665,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.1% (baseline: 117.2 ml → follow-up: 9.3 ml). This suggests treatment response. Confidence: 66.5%.
Patient-013,week-000,week-030,117.24,23.96,-93.28,-79.6,Non-Progression,Progression,PD,0.544,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -79.6% (baseline: 117.2 ml → follow-up: 24.0 ml). This suggests treatment response. Confidence: 54.4%.
Patient-014,week-000,week-012,109.15,7.15,-102.0,-93.4,Non-Progression,Non-Progression,SD,0.627,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.4% (baseline: 109.2 ml → follow-up: 7.2 ml). This suggests treatment response. Confidence: 62.7%.
Patient-015,week-000-1,week-021,50.94,4.78,-46.16,-90.6,Non-Progression,Non-Progression,CR,0.684,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.6% (baseline: 50.9 ml → follow-up: 4.8 ml). This suggests treatment response. Confidence: 68.4%.
Patient-015,week-000-1,week-037,50.94,8.79,-42.15,-82.7,Non-Progression,Non-Progression,CR,0.647,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -82.7% (baseline: 50.9 ml → follow-up: 8.8 ml). This suggests treatment response. Confidence: 64.7%.
Patient-015,week-000-1,week-056,50.94,11.82,-39.13,-76.8,Non-Progression,Progression,PD,0.627,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -76.8% (baseline: 50.9 ml → follow-up: 11.8 ml). This suggests treatment response. Confidence: 62.7%.
Patient-015,week-000-1,week-078,50.94,16.63,-34.32,-67.4,Non-Progression,Progression,PD,0.609,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -67.4% (baseline: 50.9 ml → follow-up: 16.6 ml). This suggests treatment response. Confidence: 60.9%.
Patient-015,week-000-1,week-083,50.94,15.12,-35.82,-70.3,Non-Progression,Progression,PD,0.612,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -70.3% (baseline: 50.9 ml → follow-up: 15.1 ml). This suggests treatment response. Confidence: 61.2%.
Patient-015,week-000-1,week-099,50.94,18.31,-32.63,-64.1,Non-Progression,Progression,PD,0.612,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -64.1% (baseline: 50.9 ml → follow-up: 18.3 ml). This suggests treatment response. Confidence: 61.2%.
Patient-015,week-000-1,week-111,50.94,19.71,-31.24,-61.3,Non-Progression,Progression,PD,0.601,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -61.3% (baseline: 50.9 ml → follow-up: 19.7 ml). This suggests treatment response. Confidence: 60.1%.
Patient-015,week-000-1,week-126,50.94,19.05,-31.9,-62.6,Non-Progression,Progression,PD,0.605,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -62.6% (baseline: 50.9 ml → follow-up: 19.0 ml). This suggests treatment response. Confidence: 60.5%.
Patient-015,week-000-1,week-140,50.94,34.0,-16.95,-33.3,Non-Progression,Progression,PD,0.513,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -33.3% (baseline: 50.9 ml → follow-up: 34.0 ml). This suggests treatment response. Confidence: 51.3%.
Patient-015,week-000-1,week-145,50.94,121.23,70.28,138.0,Progression,Progression,PD,0.91,True,"Predicted PROGRESSION because tumor volume increased by 138.0% between baseline (50.9 ml) and follow-up (121.2 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 91.0%."
Patient-017,week-000,week-016,32.31,20.45,-11.86,-36.7,Non-Progression,Non-Progression,SD,0.586,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -36.7% (baseline: 32.3 ml → follow-up: 20.5 ml). This suggests treatment response. Confidence: 58.6%.
Patient-017,week-000,week-035,32.31,119.55,87.24,270.0,Progression,Progression,PD,0.879,True,"Predicted PROGRESSION because tumor volume increased by 270.0% between baseline (32.3 ml) and follow-up (119.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 87.9%."
Patient-018,week-000,week-017,13.99,5.81,-8.18,-58.5,Non-Progression,Non-Progression,SD,0.663,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -58.5% (baseline: 14.0 ml → follow-up: 5.8 ml). This suggests treatment response. Confidence: 66.3%.
Patient-018,week-000,week-034,13.99,23.52,9.53,68.1,Non-Progression,Progression,PD,0.578,False,Predicted NON-PROGRESSION despite volume increase of 68.1% (baseline: 14.0 ml → follow-up: 23.5 ml). Model suggests stability based on learned patterns. Confidence: 57.8%. Close monitoring advised.
Patient-018,week-000,week-063,13.99,0.92,-13.07,-93.4,Non-Progression,Non-Progression,CR,0.698,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.4% (baseline: 14.0 ml → follow-up: 0.9 ml). This suggests treatment response. Confidence: 69.8%.
Patient-018,week-000,week-082,13.99,6.42,-7.58,-54.1,Non-Progression,Non-Progression,CR,0.66,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -54.1% (baseline: 14.0 ml → follow-up: 6.4 ml). This suggests treatment response. Confidence: 66.0%.
Patient-021,week-000-1,week-022,32.72,85.11,52.4,160.2,Progression,Progression,PD,0.764,True,"Predicted PROGRESSION because tumor volume increased by 160.2% between baseline (32.7 ml) and follow-up (85.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 76.4%."
Patient-021,week-000-1,week-035,32.72,27.38,-5.34,-16.3,Non-Progression,Non-Progression,PR,0.549,True,Predicted NON-PROGRESSION with tumor volume decrease of -16.3% (baseline: 32.7 ml → follow-up: 27.4 ml). Volume remains stable or reduced. Confidence: 54.9%.
Patient-022,week-000,week-037,110.64,147.34,36.71,33.2,Progression,Progression,PD,0.922,True,"Predicted PROGRESSION because tumor volume increased by 33.2% between baseline (110.6 ml) and follow-up (147.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 92.2%."
Patient-022,week-000,week-045,110.64,11.73,-98.9,-89.4,Non-Progression,Progression,PD,0.637,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -89.4% (baseline: 110.6 ml → follow-up: 11.7 ml). This suggests treatment response. Confidence: 63.7%.
Patient-022,week-000,week-053,110.64,64.29,-46.34,-41.9,Progression,Progression,PD,0.665,True,Predicted PROGRESSION despite apparent volume decrease of -41.9% (baseline: 110.6 ml → follow-up: 64.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 66.5%. Clinical review recommended.
Patient-023,week-000,week-024,21.18,0.0,-21.18,-100.0,Non-Progression,Non-Progression,SD,0.719,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 21.2 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 71.9%.
Patient-023,week-000,week-039,21.18,1.24,-19.93,-94.1,Non-Progression,Non-Progression,SD,0.709,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -94.1% (baseline: 21.2 ml → follow-up: 1.2 ml). This suggests treatment response. Confidence: 70.9%.
Patient-023,week-000,week-046,21.18,2.17,-19.0,-89.7,Non-Progression,Progression,PD,0.707,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -89.7% (baseline: 21.2 ml → follow-up: 2.2 ml). This suggests treatment response. Confidence: 70.7%.
Patient-023,week-000,week-059,21.18,2.76,-18.41,-86.9,Non-Progression,Progression,PD,0.701,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -86.9% (baseline: 21.2 ml → follow-up: 2.8 ml). This suggests treatment response. Confidence: 70.1%.
Patient-023,week-000,week-084,21.18,3.5,-17.67,-83.5,Non-Progression,Non-Progression,CR,0.675,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -83.5% (baseline: 21.2 ml → follow-up: 3.5 ml). This suggests treatment response. Confidence: 67.5%.
Patient-023,week-000,week-097,21.18,17.54,-3.64,-17.2,Non-Progression,Progression,PD,0.609,False,Predicted NON-PROGRESSION with tumor volume decrease of -17.2% (baseline: 21.2 ml → follow-up: 17.5 ml). Volume remains stable or reduced. Confidence: 60.9%.
Patient-023,week-000,week-111,21.18,16.76,-4.41,-20.8,Non-Progression,Progression,PD,0.613,False,Predicted NON-PROGRESSION with tumor volume decrease of -20.8% (baseline: 21.2 ml → follow-up: 16.8 ml). Volume remains stable or reduced. Confidence: 61.3%.
Patient-023,week-000,week-115,21.18,17.77,-3.41,-16.1,Non-Progression,Progression,PD,0.611,False,Predicted NON-PROGRESSION with tumor volume decrease of -16.1% (baseline: 21.2 ml → follow-up: 17.8 ml). Volume remains stable or reduced. Confidence: 61.1%.
Patient-023,week-000,week-127,21.18,189.13,167.95,793.1,Progression,Progression,PD,0.968,True,"Predicted PROGRESSION because tumor volume increased by 793.1% between baseline (21.2 ml) and follow-up (189.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 96.8%."
Patient-025,week-000,week-019,15.15,0.0,-15.15,-100.0,Non-Progression,Non-Progression,SD,0.716,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 15.1 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 71.6%.
Patient-025,week-000,week-030,15.15,1.95,-13.2,-87.1,Non-Progression,Non-Progression,SD,0.708,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.1% (baseline: 15.1 ml → follow-up: 1.9 ml). This suggests treatment response. Confidence: 70.8%.
Patient-025,week-000,week-043,15.15,6.6,-8.55,-56.4,Non-Progression,Progression,PD,0.683,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -56.4% (baseline: 15.1 ml → follow-up: 6.6 ml). This suggests treatment response. Confidence: 68.3%.
Patient-025,week-000,week-055,15.15,22.0,6.85,45.2,Non-Progression,Progression,PD,0.567,False,Predicted NON-PROGRESSION despite volume increase of 45.2% (baseline: 15.1 ml → follow-up: 22.0 ml). Model suggests stability based on learned patterns. Confidence: 56.7%. Close monitoring advised.
Patient-025,week-000,week-070,15.15,145.29,130.14,859.1,Progression,Progression,PD,0.92,True,"Predicted PROGRESSION because tumor volume increased by 859.1% between baseline (15.1 ml) and follow-up (145.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 92.0%."
Patient-027,week-000-1,week-014,62.08,75.77,13.68,22.0,Progression,Progression,PD,0.708,True,"Predicted PROGRESSION with tumor volume increase of 22.0% (baseline: 62.1 ml → follow-up: 75.8 ml). Although below the 25% heuristic threshold, the model identified progression patterns. Confidence: 70.8%."
Patient-028,week-000-1,week-015,173.38,35.3,-138.09,-79.6,Progression,Progression,PD,0.54,True,Predicted PROGRESSION despite apparent volume decrease of -79.6% (baseline: 173.4 ml → follow-up: 35.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 54.0%. Clinical review recommended.
Patient-028,week-000-1,week-030,173.38,82.99,-90.39,-52.1,Progression,Progression,PD,0.781,True,Predicted PROGRESSION despite apparent volume decrease of -52.1% (baseline: 173.4 ml → follow-up: 83.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 78.1%. Clinical review recommended.
Patient-028,week-000-1,week-038,173.38,81.82,-91.56,-52.8,Progression,Progression,PD,0.73,True,Predicted PROGRESSION despite apparent volume decrease of -52.8% (baseline: 173.4 ml → follow-up: 81.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 73.0%. Clinical review recommended.
Patient-029,week-000-1,week-010,85.86,29.58,-56.28,-65.5,Non-Progression,Non-Progression,PR,0.529,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -65.5% (baseline: 85.9 ml → follow-up: 29.6 ml). This suggests treatment response. Confidence: 52.9%.
Patient-029,week-000-1,week-022,85.86,41.43,-44.43,-51.7,Progression,Non-Progression,PR,0.542,False,Predicted PROGRESSION despite apparent volume decrease of -51.7% (baseline: 85.9 ml → follow-up: 41.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 54.2%. Clinical review recommended.
Patient-029,week-000-1,week-033,85.86,46.27,-39.58,-46.1,Progression,Non-Progression,CR,0.559,False,Predicted PROGRESSION despite apparent volume decrease of -46.1% (baseline: 85.9 ml → follow-up: 46.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 55.9%. Clinical review recommended.
Patient-029,week-000-1,week-045,85.86,58.48,-27.37,-31.9,Progression,Non-Progression,CR,0.631,False,Predicted PROGRESSION despite apparent volume decrease of -31.9% (baseline: 85.9 ml → follow-up: 58.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.1%. Clinical review recommended.
Patient-029,week-000-1,week-059,85.86,51.18,-34.68,-40.4,Progression,Non-Progression,CR,0.588,False,Predicted PROGRESSION despite apparent volume decrease of -40.4% (baseline: 85.9 ml → follow-up: 51.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 58.8%. Clinical review recommended.
Patient-029,week-000-1,week-100,85.86,59.19,-26.67,-31.1,Progression,Non-Progression,CR,0.624,False,Predicted PROGRESSION despite apparent volume decrease of -31.1% (baseline: 85.9 ml → follow-up: 59.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 62.4%. Clinical review recommended.
Patient-029,week-000-1,week-112,85.86,56.04,-29.82,-34.7,Progression,Non-Progression,CR,0.619,False,Predicted PROGRESSION despite apparent volume decrease of -34.7% (baseline: 85.9 ml → follow-up: 56.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 61.9%. Clinical review recommended.
Patient-029,week-000-1,week-152,85.86,50.0,-35.86,-41.8,Progression,Non-Progression,CR,0.581,False,Predicted PROGRESSION despite apparent volume decrease of -41.8% (baseline: 85.9 ml → follow-up: 50.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 58.1%. Clinical review recommended.
Patient-029,week-000-1,week-165,85.86,51.96,-33.9,-39.5,Progression,Non-Progression,CR,0.61,False,Predicted PROGRESSION despite apparent volume decrease of -39.5% (baseline: 85.9 ml → follow-up: 52.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 61.0%. Clinical review recommended.
Patient-029,week-000-1,week-207,85.86,43.42,-42.44,-49.4,Progression,Non-Progression,CR,0.538,False,Predicted PROGRESSION despite apparent volume decrease of -49.4% (baseline: 85.9 ml → follow-up: 43.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.8%. Clinical review recommended.
Patient-029,week-000-1,week-223,85.86,36.14,-49.72,-57.9,Non-Progression,Progression,PD,0.503,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -57.9% (baseline: 85.9 ml → follow-up: 36.1 ml). This suggests treatment response. Confidence: 50.3%.
Patient-030,week-000,week-017,31.35,3.39,-27.96,-89.2,Non-Progression,Non-Progression,SD,0.678,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -89.2% (baseline: 31.3 ml → follow-up: 3.4 ml). This suggests treatment response. Confidence: 67.8%.
Patient-030,week-000,week-025,31.35,3.13,-28.22,-90.0,Non-Progression,Non-Progression,SD,0.682,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.0% (baseline: 31.3 ml → follow-up: 3.1 ml). This suggests treatment response. Confidence: 68.2%.
Patient-030,week-000,week-041,31.35,3.17,-28.18,-89.9,Non-Progression,Progression,PD,0.681,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -89.9% (baseline: 31.3 ml → follow-up: 3.2 ml). This suggests treatment response. Confidence: 68.1%.
Patient-030,week-000,week-052,31.35,31.71,0.36,1.2,Non-Progression,Progression,PD,0.52,False,Predicted NON-PROGRESSION (stable disease) with volume change of 1.2% (baseline: 31.3 ml → follow-up: 31.7 ml). Change is within the 25% stability threshold inspired by RANO criteria. Confidence: 52.0%.
Patient-030,week-000,week-067,31.35,19.2,-12.14,-38.7,Non-Progression,Non-Progression,PR,0.592,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -38.7% (baseline: 31.3 ml → follow-up: 19.2 ml). This suggests treatment response. Confidence: 59.2%.
Patient-030,week-000,week-085,31.35,50.71,19.36,61.8,Progression,Progression,PD,0.559,True,"Predicted PROGRESSION because tumor volume increased by 61.8% between baseline (31.3 ml) and follow-up (50.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 55.9%."
Patient-031,week-000,week-015,63.59,15.52,-48.08,-75.6,Non-Progression,Non-Progression,SD,0.624,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -75.6% (baseline: 63.6 ml → follow-up: 15.5 ml). This suggests treatment response. Confidence: 62.4%.
Patient-031,week-000,week-032,63.59,5.86,-57.74,-90.8,Non-Progression,Non-Progression,CR,0.65,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.8% (baseline: 63.6 ml → follow-up: 5.9 ml). This suggests treatment response. Confidence: 65.0%.
Patient-031,week-000,week-046,63.59,10.75,-52.84,-83.1,Non-Progression,Non-Progression,CR,0.656,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -83.1% (baseline: 63.6 ml → follow-up: 10.8 ml). This suggests treatment response. Confidence: 65.6%.
Patient-031,week-000,week-059,63.59,12.46,-51.14,-80.4,Non-Progression,Non-Progression,CR,0.62,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -80.4% (baseline: 63.6 ml → follow-up: 12.5 ml). This suggests treatment response. Confidence: 62.0%.
Patient-031,week-000,week-074,63.59,10.71,-52.88,-83.2,Non-Progression,Non-Progression,CR,0.633,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -83.2% (baseline: 63.6 ml → follow-up: 10.7 ml). This suggests treatment response. Confidence: 63.3%.
Patient-031,week-000,week-087,63.59,13.92,-49.67,-78.1,Non-Progression,Non-Progression,CR,0.625,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.1% (baseline: 63.6 ml → follow-up: 13.9 ml). This suggests treatment response. Confidence: 62.5%.
Patient-031,week-000,week-105,63.59,13.3,-50.3,-79.1,Non-Progression,Non-Progression,CR,0.62,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -79.1% (baseline: 63.6 ml → follow-up: 13.3 ml). This suggests treatment response. Confidence: 62.0%.
Patient-031,week-000,week-123,63.59,13.41,-50.18,-78.9,Non-Progression,Non-Progression,CR,0.627,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.9% (baseline: 63.6 ml → follow-up: 13.4 ml). This suggests treatment response. Confidence: 62.7%.
Patient-031,week-000,week-142,63.59,14.44,-49.16,-77.3,Non-Progression,Progression,PD,0.614,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -77.3% (baseline: 63.6 ml → follow-up: 14.4 ml). This suggests treatment response. Confidence: 61.4%.
Patient-031,week-000,week-151,63.59,60.45,-3.14,-4.9,Progression,Progression,PD,0.634,True,Predicted PROGRESSION despite apparent volume decrease of -4.9% (baseline: 63.6 ml → follow-up: 60.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.4%. Clinical review recommended.
Patient-031,week-000,week-165,63.59,13.54,-50.05,-78.7,Non-Progression,Progression,PD,0.619,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.7% (baseline: 63.6 ml → follow-up: 13.5 ml). This suggests treatment response. Confidence: 61.9%.
Patient-031,week-000,week-184,63.59,85.55,21.96,34.5,Progression,Progression,PD,0.751,True,"Predicted PROGRESSION because tumor volume increased by 34.5% between baseline (63.6 ml) and follow-up (85.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 75.1%."
Patient-031,week-000,week-190,63.59,189.67,126.08,198.3,Progression,Progression,PD,0.953,True,"Predicted PROGRESSION because tumor volume increased by 198.3% between baseline (63.6 ml) and follow-up (189.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 95.3%."
Patient-032,week-000-1,week-013,38.01,1.24,-36.77,-96.7,Non-Progression,Non-Progression,CR,0.712,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -96.7% (baseline: 38.0 ml → follow-up: 1.2 ml). This suggests treatment response. Confidence: 71.2%.
Patient-032,week-000-1,week-027,38.01,8.14,-29.87,-78.6,Non-Progression,Non-Progression,CR,0.655,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.6% (baseline: 38.0 ml → follow-up: 8.1 ml). This suggests treatment response. Confidence: 65.5%.
Patient-032,week-000-1,week-040,38.01,10.14,-27.87,-73.3,Non-Progression,Non-Progression,CR,0.643,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -73.3% (baseline: 38.0 ml → follow-up: 10.1 ml). This suggests treatment response. Confidence: 64.3%.
Patient-032,week-000-1,week-044,38.01,12.03,-25.97,-68.3,Non-Progression,Progression,PD,0.633,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -68.3% (baseline: 38.0 ml → follow-up: 12.0 ml). This suggests treatment response. Confidence: 63.3%.
Patient-032,week-000-1,week-055,38.01,12.72,-25.29,-66.5,Non-Progression,Progression,PD,0.631,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -66.5% (baseline: 38.0 ml → follow-up: 12.7 ml). This suggests treatment response. Confidence: 63.1%.
Patient-032,week-000-1,week-067,38.01,16.6,-21.41,-56.3,Non-Progression,Progression,PD,0.62,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -56.3% (baseline: 38.0 ml → follow-up: 16.6 ml). This suggests treatment response. Confidence: 62.0%.
Patient-032,week-000-1,week-075,38.01,9.95,-28.06,-73.8,Non-Progression,Progression,PD,0.646,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -73.8% (baseline: 38.0 ml → follow-up: 9.9 ml). This suggests treatment response. Confidence: 64.6%.
Patient-032,week-000-1,week-085,38.01,15.72,-22.29,-58.7,Non-Progression,Non-Progression,CR,0.629,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -58.7% (baseline: 38.0 ml → follow-up: 15.7 ml). This suggests treatment response. Confidence: 62.9%.
Patient-032,week-000-1,week-096,38.01,15.93,-22.08,-58.1,Non-Progression,Progression,PD,0.628,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -58.1% (baseline: 38.0 ml → follow-up: 15.9 ml). This suggests treatment response. Confidence: 62.8%.
Patient-033,week-000,week-006,57.17,4.02,-53.15,-93.0,Non-Progression,Non-Progression,SD,0.696,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.0% (baseline: 57.2 ml → follow-up: 4.0 ml). This suggests treatment response. Confidence: 69.6%.
Patient-033,week-000,week-031,57.17,14.63,-42.54,-74.4,Non-Progression,Progression,PD,0.63,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -74.4% (baseline: 57.2 ml → follow-up: 14.6 ml). This suggests treatment response. Confidence: 63.0%.
Patient-033,week-000,week-049,57.17,14.9,-42.27,-73.9,Non-Progression,Progression,PD,0.629,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -73.9% (baseline: 57.2 ml → follow-up: 14.9 ml). This suggests treatment response. Confidence: 62.9%.
Patient-033,week-000,week-063,57.17,19.38,-37.79,-66.1,Non-Progression,Progression,PD,0.604,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -66.1% (baseline: 57.2 ml → follow-up: 19.4 ml). This suggests treatment response. Confidence: 60.4%.
Patient-033,week-000,week-076,57.17,22.85,-34.32,-60.0,Non-Progression,Progression,PD,0.571,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -60.0% (baseline: 57.2 ml → follow-up: 22.8 ml). This suggests treatment response. Confidence: 57.1%.
Patient-033,week-000,week-084,57.17,21.16,-36.01,-63.0,Non-Progression,Progression,PD,0.581,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -63.0% (baseline: 57.2 ml → follow-up: 21.2 ml). This suggests treatment response. Confidence: 58.1%.
Patient-034,week-000-1,week-014,173.29,8.19,-165.1,-95.3,Non-Progression,Non-Progression,SD,0.654,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -95.3% (baseline: 173.3 ml → follow-up: 8.2 ml). This suggests treatment response. Confidence: 65.4%.
Patient-034,week-000-1,week-028,173.29,11.09,-162.2,-93.6,Non-Progression,Progression,PD,0.64,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.6% (baseline: 173.3 ml → follow-up: 11.1 ml). This suggests treatment response. Confidence: 64.0%.
Patient-034,week-000-1,week-040,173.29,29.14,-144.16,-83.2,Progression,Progression,PD,0.504,True,Predicted PROGRESSION despite apparent volume decrease of -83.2% (baseline: 173.3 ml → follow-up: 29.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 50.4%. Clinical review recommended.
Patient-034,week-000-1,week-058,173.29,35.68,-137.61,-79.4,Progression,Progression,PD,0.505,True,Predicted PROGRESSION despite apparent volume decrease of -79.4% (baseline: 173.3 ml → follow-up: 35.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 50.5%. Clinical review recommended.
Patient-035,week-000-2,week-008,71.56,106.47,34.91,48.8,Progression,Non-Progression,SD,0.828,False,"Predicted PROGRESSION because tumor volume increased by 48.8% between baseline (71.6 ml) and follow-up (106.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 82.8%."
Patient-035,week-000-2,week-019,71.56,40.9,-30.66,-42.8,Progression,Non-Progression,SD,0.533,False,Predicted PROGRESSION despite apparent volume decrease of -42.8% (baseline: 71.6 ml → follow-up: 40.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.3%. Clinical review recommended.
Patient-035,week-000-2,week-024,71.56,63.45,-8.11,-11.3,Progression,Progression,PD,0.652,True,Predicted PROGRESSION despite apparent volume decrease of -11.3% (baseline: 71.6 ml → follow-up: 63.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 65.2%. Clinical review recommended.
Patient-035,week-000-2,week-036,71.56,111.94,40.38,56.4,Progression,Progression,PD,0.886,True,"Predicted PROGRESSION because tumor volume increased by 56.4% between baseline (71.6 ml) and follow-up (111.9 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 88.6%."
Patient-035,week-000-2,week-050,71.56,135.25,63.69,89.0,Progression,Progression,PD,0.935,True,"Predicted PROGRESSION because tumor volume increased by 89.0% between baseline (71.6 ml) and follow-up (135.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 93.5%."
Patient-036,week-000,week-005,7.19,0.55,-6.64,-92.4,Non-Progression,Non-Progression,SD,0.693,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.4% (baseline: 7.2 ml → follow-up: 0.5 ml). This suggests treatment response. Confidence: 69.3%.
Patient-037,week-000-1,week-002,24.13,24.54,0.4,1.7,Non-Progression,Non-Progression,SD,0.559,True,Predicted NON-PROGRESSION (stable disease) with volume change of 1.7% (baseline: 24.1 ml → follow-up: 24.5 ml). Change is within the 25% stability threshold inspired by RANO criteria. Confidence: 55.9%.
Patient-037,week-000-1,week-015,24.13,66.34,42.21,174.9,Progression,Non-Progression,SD,0.706,False,"Predicted PROGRESSION because tumor volume increased by 174.9% between baseline (24.1 ml) and follow-up (66.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 70.6%."
Patient-037,week-000-1,week-025,24.13,51.15,27.02,112.0,Progression,Non-Progression,SD,0.562,False,"Predicted PROGRESSION because tumor volume increased by 112.0% between baseline (24.1 ml) and follow-up (51.2 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 56.2%."
Patient-037,week-000-1,week-029,24.13,69.51,45.38,188.0,Progression,Progression,PD,0.7,True,"Predicted PROGRESSION because tumor volume increased by 188.0% between baseline (24.1 ml) and follow-up (69.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 70.0%."
Patient-037,week-000-1,week-037,24.13,71.42,47.29,195.9,Progression,Progression,PD,0.709,True,"Predicted PROGRESSION because tumor volume increased by 195.9% between baseline (24.1 ml) and follow-up (71.4 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 70.9%."
Patient-038,week-000,week-023,45.69,49.37,3.68,8.1,Progression,Progression,PD,0.57,True,"Predicted PROGRESSION with tumor volume increase of 8.1% (baseline: 45.7 ml → follow-up: 49.4 ml). Although below the 25% heuristic threshold, the model identified progression patterns. Confidence: 57.0%."
Patient-039,week-000-1,week-017,134.19,2.38,-131.81,-98.2,Non-Progression,Non-Progression,SD,0.676,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -98.2% (baseline: 134.2 ml → follow-up: 2.4 ml). This suggests treatment response. Confidence: 67.6%.
Patient-039,week-000-1,week-044,134.19,49.67,-84.52,-63.0,Progression,Progression,PD,0.592,True,Predicted PROGRESSION despite apparent volume decrease of -63.0% (baseline: 134.2 ml → follow-up: 49.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 59.2%. Clinical review recommended.
Patient-040,week-000,week-015,17.18,132.98,115.8,674.1,Progression,Non-Progression,SD,0.94,False,"Predicted PROGRESSION because tumor volume increased by 674.1% between baseline (17.2 ml) and follow-up (133.0 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 94.0%."
Patient-040,week-000,week-028,17.18,163.96,146.78,854.5,Progression,Progression,PD,0.963,True,"Predicted PROGRESSION because tumor volume increased by 854.5% between baseline (17.2 ml) and follow-up (164.0 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 96.3%."
Patient-041,week-000,week-020,96.0,24.42,-71.58,-74.6,Non-Progression,Non-Progression,SD,0.57,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -74.6% (baseline: 96.0 ml → follow-up: 24.4 ml). This suggests treatment response. Confidence: 57.0%.
Patient-041,week-000,week-038,96.0,7.57,-88.43,-92.1,Non-Progression,Progression,PD,0.658,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.1% (baseline: 96.0 ml → follow-up: 7.6 ml). This suggests treatment response. Confidence: 65.8%.
Patient-042,week-000-1,week-004,62.75,1.09,-61.65,-98.3,Non-Progression,Non-Progression,SD,0.671,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -98.3% (baseline: 62.7 ml → follow-up: 1.1 ml). This suggests treatment response. Confidence: 67.1%.
Patient-042,week-000-1,week-010,62.75,0.03,-62.72,-100.0,Non-Progression,Non-Progression,SD,0.718,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 62.7 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 71.8%.
Patient-042,week-000-1,week-010,62.75,0.03,-62.72,-100.0,Non-Progression,Progression,PD,0.718,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 62.7 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 71.8%.
Patient-042,week-000-1,week-022,62.75,0.47,-62.28,-99.3,Non-Progression,Non-Progression,SD,0.715,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -99.3% (baseline: 62.7 ml → follow-up: 0.5 ml). This suggests treatment response. Confidence: 71.5%.
Patient-042,week-000-1,week-035,62.75,1.77,-60.98,-97.2,Non-Progression,Non-Progression,SD,0.687,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -97.2% (baseline: 62.7 ml → follow-up: 1.8 ml). This suggests treatment response. Confidence: 68.7%.
Patient-042,week-000-1,week-055,62.75,7.88,-54.87,-87.4,Non-Progression,Progression,PD,0.665,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.4% (baseline: 62.7 ml → follow-up: 7.9 ml). This suggests treatment response. Confidence: 66.5%.
Patient-042,week-000-1,week-060,62.75,22.55,-40.2,-64.1,Non-Progression,Progression,PD,0.572,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -64.1% (baseline: 62.7 ml → follow-up: 22.5 ml). This suggests treatment response. Confidence: 57.2%.
Patient-042,week-000-1,week-061-1,62.75,24.57,-38.18,-60.8,Non-Progression,Progression,PD,0.573,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -60.8% (baseline: 62.7 ml → follow-up: 24.6 ml). This suggests treatment response. Confidence: 57.3%.
Patient-042,week-000-1,week-078,62.75,55.08,-7.66,-12.2,Progression,Progression,PD,0.606,True,Predicted PROGRESSION despite apparent volume decrease of -12.2% (baseline: 62.7 ml → follow-up: 55.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.6%. Clinical review recommended.
Patient-042,week-000-1,week-081,62.75,150.28,87.54,139.5,Progression,Progression,PD,0.926,True,"Predicted PROGRESSION because tumor volume increased by 139.5% between baseline (62.7 ml) and follow-up (150.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 92.6%."
Patient-043,week-000,week-018,1.8,0.0,-1.8,-100.0,Non-Progression,Non-Progression,SD,0.698,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 1.8 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 69.8%.
Patient-043,week-000,week-030,1.8,0.0,-1.8,-100.0,Non-Progression,Non-Progression,SD,0.719,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -100.0% (baseline: 1.8 ml → follow-up: 0.0 ml). This suggests treatment response. Confidence: 71.9%.
Patient-043,week-000,week-041,1.8,0.14,-1.66,-92.0,Non-Progression,Non-Progression,SD,0.697,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.0% (baseline: 1.8 ml → follow-up: 0.1 ml). This suggests treatment response. Confidence: 69.7%.
Patient-043,week-000,week-053,1.8,0.41,-1.39,-77.4,Non-Progression,Non-Progression,SD,0.717,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -77.4% (baseline: 1.8 ml → follow-up: 0.4 ml). This suggests treatment response. Confidence: 71.7%.
Patient-043,week-000,week-067,1.8,0.17,-1.63,-90.7,Non-Progression,Progression,PD,0.694,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.7% (baseline: 1.8 ml → follow-up: 0.2 ml). This suggests treatment response. Confidence: 69.4%.
Patient-043,week-000,week-084,1.8,3.72,1.92,106.8,Non-Progression,Progression,PD,0.683,False,Predicted NON-PROGRESSION despite volume increase of 106.8% (baseline: 1.8 ml → follow-up: 3.7 ml). Model suggests stability based on learned patterns. Confidence: 68.3%. Close monitoring advised.
Patient-043,week-000,week-098,1.8,9.7,7.9,438.9,Non-Progression,Progression,PD,0.633,False,Predicted NON-PROGRESSION despite volume increase of 438.9% (baseline: 1.8 ml → follow-up: 9.7 ml). Model suggests stability based on learned patterns. Confidence: 63.3%. Close monitoring advised.
Patient-043,week-000,week-106,1.8,34.19,32.39,1799.4,Progression,Progression,PD,0.542,True,"Predicted PROGRESSION because tumor volume increased by 1799.4% between baseline (1.8 ml) and follow-up (34.2 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 54.2%."
Patient-043,week-000,week-116,1.8,46.96,45.16,2508.9,Progression,Progression,PD,0.62,True,"Predicted PROGRESSION because tumor volume increased by 2508.9% between baseline (1.8 ml) and follow-up (47.0 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 62.0%."
Patient-045,week-000-1,week-017,16.41,18.37,1.97,12.0,Non-Progression,Non-Progression,SD,0.605,True,Predicted NON-PROGRESSION (stable disease) with volume change of 12.0% (baseline: 16.4 ml → follow-up: 18.4 ml). Change is within the 25% stability threshold inspired by RANO criteria. Confidence: 60.5%.
Patient-045,week-000-1,week-028,16.41,42.6,26.19,159.6,Progression,Progression,PD,0.562,True,"Predicted PROGRESSION because tumor volume increased by 159.6% between baseline (16.4 ml) and follow-up (42.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 56.2%."
Patient-046,week-000,week-016,10.24,10.2,-0.04,-0.4,Non-Progression,Non-Progression,SD,0.652,True,Predicted NON-PROGRESSION with tumor volume decrease of -0.4% (baseline: 10.2 ml → follow-up: 10.2 ml). Volume remains stable or reduced. Confidence: 65.2%.
Patient-046,week-000,week-064,10.24,66.48,56.24,549.2,Progression,Progression,PD,0.655,True,"Predicted PROGRESSION because tumor volume increased by 549.2% between baseline (10.2 ml) and follow-up (66.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 65.5%."
Patient-048,week-000-1,week-013,126.82,3.12,-123.7,-97.5,Non-Progression,Non-Progression,SD,0.65,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -97.5% (baseline: 126.8 ml → follow-up: 3.1 ml). This suggests treatment response. Confidence: 65.0%.
Patient-048,week-000-1,week-023,126.82,6.77,-120.04,-94.7,Non-Progression,Non-Progression,CR,0.622,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -94.7% (baseline: 126.8 ml → follow-up: 6.8 ml). This suggests treatment response. Confidence: 62.2%.
Patient-048,week-000-1,week-045,126.82,9.06,-117.75,-92.9,Non-Progression,Progression,PD,0.619,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.9% (baseline: 126.8 ml → follow-up: 9.1 ml). This suggests treatment response. Confidence: 61.9%.
Patient-048,week-000-1,week-049,126.82,72.18,-54.63,-43.1,Progression,Progression,PD,0.687,True,Predicted PROGRESSION despite apparent volume decrease of -43.1% (baseline: 126.8 ml → follow-up: 72.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 68.7%. Clinical review recommended.
Patient-049,week-000,week-019,16.86,112.91,96.05,569.7,Progression,Non-Progression,SD,0.881,False,"Predicted PROGRESSION because tumor volume increased by 569.7% between baseline (16.9 ml) and follow-up (112.9 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 88.1%."
Patient-049,week-000,week-029,16.86,79.53,62.67,371.7,Progression,Progression,PD,0.72,True,"Predicted PROGRESSION because tumor volume increased by 371.7% between baseline (16.9 ml) and follow-up (79.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 72.0%."
Patient-049,week-000,week-046,16.86,207.67,190.81,1131.7,Progression,Progression,PD,0.972,True,"Predicted PROGRESSION because tumor volume increased by 1131.7% between baseline (16.9 ml) and follow-up (207.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 97.2%."
Patient-050,week-000,week-048,41.98,118.71,76.73,182.8,Progression,Progression,PD,0.872,True,"Predicted PROGRESSION because tumor volume increased by 182.8% between baseline (42.0 ml) and follow-up (118.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 87.2%."
Patient-050,week-000,week-061,41.98,221.41,179.43,427.5,Progression,Progression,PD,0.983,True,"Predicted PROGRESSION because tumor volume increased by 427.5% between baseline (42.0 ml) and follow-up (221.4 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 98.3%."
Patient-051,week-000-1,week-012,159.41,51.38,-108.03,-67.8,Progression,Non-Progression,SD,0.605,False,Predicted PROGRESSION despite apparent volume decrease of -67.8% (baseline: 159.4 ml → follow-up: 51.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.5%. Clinical review recommended.
Patient-051,week-000-1,week-023,159.41,92.88,-66.53,-41.7,Progression,Progression,PD,0.822,True,Predicted PROGRESSION despite apparent volume decrease of -41.7% (baseline: 159.4 ml → follow-up: 92.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 82.2%. Clinical review recommended.
Patient-051,week-000-1,week-036,159.41,59.5,-99.91,-62.7,Progression,Progression,PD,0.657,True,Predicted PROGRESSION despite apparent volume decrease of -62.7% (baseline: 159.4 ml → follow-up: 59.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 65.7%. Clinical review recommended.
Patient-051,week-000-1,week-050,159.41,50.5,-108.91,-68.3,Progression,Progression,PD,0.603,True,Predicted PROGRESSION despite apparent volume decrease of -68.3% (baseline: 159.4 ml → follow-up: 50.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.3%. Clinical review recommended.
Patient-051,week-000-1,week-064,159.41,52.26,-107.15,-67.2,Progression,Progression,PD,0.625,True,Predicted PROGRESSION despite apparent volume decrease of -67.2% (baseline: 159.4 ml → follow-up: 52.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 62.5%. Clinical review recommended.
Patient-051,week-000-1,week-077,159.41,55.3,-104.11,-65.3,Progression,Progression,PD,0.64,True,Predicted PROGRESSION despite apparent volume decrease of -65.3% (baseline: 159.4 ml → follow-up: 55.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 64.0%. Clinical review recommended.
Patient-051,week-000-1,week-089,159.41,68.9,-90.51,-56.8,Progression,Progression,PD,0.67,True,Predicted PROGRESSION despite apparent volume decrease of -56.8% (baseline: 159.4 ml → follow-up: 68.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 67.0%. Clinical review recommended.
Patient-051,week-000-1,week-103,159.41,75.88,-83.53,-52.4,Progression,Progression,PD,0.747,True,Predicted PROGRESSION despite apparent volume decrease of -52.4% (baseline: 159.4 ml → follow-up: 75.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 74.7%. Clinical review recommended.
Patient-052,week-000,week-089,88.34,37.38,-50.96,-57.7,Progression,Progression,PD,0.515,True,Predicted PROGRESSION despite apparent volume decrease of -57.7% (baseline: 88.3 ml → follow-up: 37.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.5%. Clinical review recommended.
Patient-052,week-000,week-115,88.34,39.63,-48.71,-55.1,Progression,Progression,PD,0.53,True,Predicted PROGRESSION despite apparent volume decrease of -55.1% (baseline: 88.3 ml → follow-up: 39.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.0%. Clinical review recommended.
Patient-052,week-000,week-133,88.34,48.27,-40.07,-45.4,Progression,Progression,PD,0.565,True,Predicted PROGRESSION despite apparent volume decrease of -45.4% (baseline: 88.3 ml → follow-up: 48.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 56.5%. Clinical review recommended.
Patient-052,week-000,week-148,88.34,55.2,-33.14,-37.5,Progression,Progression,PD,0.611,True,Predicted PROGRESSION despite apparent volume decrease of -37.5% (baseline: 88.3 ml → follow-up: 55.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 61.1%. Clinical review recommended.
Patient-052,week-000,week-168,88.34,70.58,-17.76,-20.1,Progression,Progression,PD,0.681,True,Predicted PROGRESSION despite apparent volume decrease of -20.1% (baseline: 88.3 ml → follow-up: 70.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 68.1%. Clinical review recommended.
Patient-055,week-000-1,week-017,128.54,4.9,-123.64,-96.2,Non-Progression,Non-Progression,SD,0.64,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -96.2% (baseline: 128.5 ml → follow-up: 4.9 ml). This suggests treatment response. Confidence: 64.0%.
Patient-055,week-000-1,week-039,128.54,9.02,-119.52,-93.0,Non-Progression,Progression,PD,0.65,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.0% (baseline: 128.5 ml → follow-up: 9.0 ml). This suggests treatment response. Confidence: 65.0%.
Patient-055,week-000-1,week-054,128.54,9.16,-119.38,-92.9,Non-Progression,Progression,PD,0.618,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -92.9% (baseline: 128.5 ml → follow-up: 9.2 ml). This suggests treatment response. Confidence: 61.8%.
Patient-055,week-000-1,week-067,128.54,11.54,-116.99,-91.0,Non-Progression,Progression,PD,0.629,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -91.0% (baseline: 128.5 ml → follow-up: 11.5 ml). This suggests treatment response. Confidence: 62.9%.
Patient-055,week-000-1,week-084,128.54,60.99,-67.55,-52.5,Progression,Progression,PD,0.631,True,Predicted PROGRESSION despite apparent volume decrease of -52.5% (baseline: 128.5 ml → follow-up: 61.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.1%. Clinical review recommended.
Patient-055,week-000-1,week-099,128.54,46.79,-81.75,-63.6,Progression,Progression,PD,0.577,True,Predicted PROGRESSION despite apparent volume decrease of -63.6% (baseline: 128.5 ml → follow-up: 46.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 57.7%. Clinical review recommended.
Patient-055,week-000-1,week-118,128.54,63.42,-65.11,-50.7,Progression,Progression,PD,0.665,True,Predicted PROGRESSION despite apparent volume decrease of -50.7% (baseline: 128.5 ml → follow-up: 63.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 66.5%. Clinical review recommended.
Patient-059,week-000,week-014,8.55,57.36,48.81,570.7,Progression,Progression,PD,0.615,True,"Predicted PROGRESSION because tumor volume increased by 570.7% between baseline (8.6 ml) and follow-up (57.4 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 61.5%."
Patient-059,week-000,week-024,8.55,95.58,87.03,1017.5,Progression,Progression,PD,0.866,True,"Predicted PROGRESSION because tumor volume increased by 1017.5% between baseline (8.6 ml) and follow-up (95.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 86.6%."
Patient-059,week-000,week-040,8.55,72.27,63.72,745.0,Progression,Progression,PD,0.691,True,"Predicted PROGRESSION because tumor volume increased by 745.0% between baseline (8.6 ml) and follow-up (72.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 69.1%."
Patient-059,week-000,week-055,8.55,31.58,23.02,269.2,Non-Progression,Non-Progression,PR,0.535,True,Predicted NON-PROGRESSION despite volume increase of 269.2% (baseline: 8.6 ml → follow-up: 31.6 ml). Model suggests stability based on learned patterns. Confidence: 53.5%. Close monitoring advised.
Patient-059,week-000,week-068,8.55,29.35,20.8,243.2,Non-Progression,Progression,PD,0.545,False,Predicted NON-PROGRESSION despite volume increase of 243.2% (baseline: 8.6 ml → follow-up: 29.4 ml). Model suggests stability based on learned patterns. Confidence: 54.5%. Close monitoring advised.
Patient-059,week-000,week-084,8.55,39.1,30.55,357.2,Progression,Progression,PD,0.514,True,"Predicted PROGRESSION because tumor volume increased by 357.2% between baseline (8.6 ml) and follow-up (39.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 51.4%."
Patient-059,week-000,week-100,8.55,28.39,19.83,231.9,Non-Progression,Non-Progression,PR,0.546,True,Predicted NON-PROGRESSION despite volume increase of 231.9% (baseline: 8.6 ml → follow-up: 28.4 ml). Model suggests stability based on learned patterns. Confidence: 54.6%. Close monitoring advised.
Patient-059,week-000,week-116,8.55,24.18,15.63,182.8,Non-Progression,Non-Progression,PR,0.569,True,Predicted NON-PROGRESSION despite volume increase of 182.8% (baseline: 8.6 ml → follow-up: 24.2 ml). Model suggests stability based on learned patterns. Confidence: 56.9%. Close monitoring advised.
Patient-059,week-000,week-136,8.55,21.64,13.08,153.0,Non-Progression,Progression,PD,0.554,False,Predicted NON-PROGRESSION despite volume increase of 153.0% (baseline: 8.6 ml → follow-up: 21.6 ml). Model suggests stability based on learned patterns. Confidence: 55.4%. Close monitoring advised.
Patient-060,week-000,week-031,71.44,1.79,-69.66,-97.5,Non-Progression,Non-Progression,SD,0.687,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -97.5% (baseline: 71.4 ml → follow-up: 1.8 ml). This suggests treatment response. Confidence: 68.7%.
Patient-060,week-000,week-052,71.44,4.18,-67.27,-94.2,Non-Progression,Non-Progression,SD,0.663,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -94.2% (baseline: 71.4 ml → follow-up: 4.2 ml). This suggests treatment response. Confidence: 66.3%.
Patient-060,week-000,week-065,71.44,8.98,-62.47,-87.4,Non-Progression,Progression,PD,0.651,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.4% (baseline: 71.4 ml → follow-up: 9.0 ml). This suggests treatment response. Confidence: 65.1%.
Patient-060,week-000,week-088,71.44,23.2,-48.24,-67.5,Non-Progression,Progression,PD,0.565,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -67.5% (baseline: 71.4 ml → follow-up: 23.2 ml). This suggests treatment response. Confidence: 56.5%.
Patient-061,week-000-1,week-022,106.89,26.65,-80.25,-75.1,Non-Progression,Progression,PD,0.556,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -75.1% (baseline: 106.9 ml → follow-up: 26.6 ml). This suggests treatment response. Confidence: 55.6%.
Patient-061,week-000-1,week-027,106.89,30.02,-76.87,-71.9,Non-Progression,Progression,PD,0.518,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -71.9% (baseline: 106.9 ml → follow-up: 30.0 ml). This suggests treatment response. Confidence: 51.8%.
Patient-061,week-000-1,week-034,106.89,30.32,-76.57,-71.6,Non-Progression,Progression,PD,0.536,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -71.6% (baseline: 106.9 ml → follow-up: 30.3 ml). This suggests treatment response. Confidence: 53.6%.
Patient-061,week-000-1,week-054,106.89,146.85,39.95,37.4,Progression,Progression,PD,0.902,True,"Predicted PROGRESSION because tumor volume increased by 37.4% between baseline (106.9 ml) and follow-up (146.8 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 90.2%."
Patient-062,week-000-1,week-015,96.99,6.82,-90.17,-93.0,Non-Progression,Non-Progression,SD,0.662,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.0% (baseline: 97.0 ml → follow-up: 6.8 ml). This suggests treatment response. Confidence: 66.2%.
Patient-062,week-000-1,week-030,96.99,18.98,-78.0,-80.4,Non-Progression,Non-Progression,SD,0.576,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -80.4% (baseline: 97.0 ml → follow-up: 19.0 ml). This suggests treatment response. Confidence: 57.6%.
Patient-062,week-000-1,week-042,96.99,23.54,-73.45,-75.7,Non-Progression,Non-Progression,SD,0.57,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -75.7% (baseline: 97.0 ml → follow-up: 23.5 ml). This suggests treatment response. Confidence: 57.0%.
Patient-062,week-000-1,week-050,96.99,34.76,-62.23,-64.2,Non-Progression,Progression,PD,0.505,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -64.2% (baseline: 97.0 ml → follow-up: 34.8 ml). This suggests treatment response. Confidence: 50.5%.
Patient-062,week-000-1,week-057,96.99,37.56,-59.43,-61.3,Progression,Progression,PD,0.515,True,Predicted PROGRESSION despite apparent volume decrease of -61.3% (baseline: 97.0 ml → follow-up: 37.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.5%. Clinical review recommended.
Patient-062,week-000-1,week-064,96.99,101.27,4.28,4.4,Progression,Progression,PD,0.823,True,"Predicted PROGRESSION with tumor volume increase of 4.4% (baseline: 97.0 ml → follow-up: 101.3 ml). Although below the 25% heuristic threshold, the model identified progression patterns. Confidence: 82.3%."
Patient-064,week-000,week-020,83.19,40.48,-42.71,-51.3,Progression,Non-Progression,SD,0.534,False,Predicted PROGRESSION despite apparent volume decrease of -51.3% (baseline: 83.2 ml → follow-up: 40.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.4%. Clinical review recommended.
Patient-064,week-000,week-033,83.19,39.08,-44.11,-53.0,Progression,Progression,PD,0.527,True,Predicted PROGRESSION despite apparent volume decrease of -53.0% (baseline: 83.2 ml → follow-up: 39.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 52.7%. Clinical review recommended.
Patient-064,week-000,week-049,83.19,39.12,-44.07,-53.0,Progression,Non-Progression,SD,0.517,False,Predicted PROGRESSION despite apparent volume decrease of -53.0% (baseline: 83.2 ml → follow-up: 39.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.7%. Clinical review recommended.
Patient-064,week-000,week-062,83.19,36.3,-46.89,-56.4,Progression,Progression,PD,0.508,True,Predicted PROGRESSION despite apparent volume decrease of -56.4% (baseline: 83.2 ml → follow-up: 36.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 50.8%. Clinical review recommended.
Patient-065,week-000-2,week-014,28.85,13.03,-15.82,-54.8,Non-Progression,Non-Progression,SD,0.627,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -54.8% (baseline: 28.9 ml → follow-up: 13.0 ml). This suggests treatment response. Confidence: 62.7%.
Patient-065,week-000-2,week-021,28.85,18.34,-10.52,-36.4,Non-Progression,Progression,PD,0.616,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -36.4% (baseline: 28.9 ml → follow-up: 18.3 ml). This suggests treatment response. Confidence: 61.6%.
Patient-065,week-000-2,week-029,28.85,16.68,-12.18,-42.2,Non-Progression,Progression,PD,0.626,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -42.2% (baseline: 28.9 ml → follow-up: 16.7 ml). This suggests treatment response. Confidence: 62.6%.
Patient-065,week-000-2,week-079,28.85,295.16,266.3,922.9,Progression,Progression,PD,0.998,True,"Predicted PROGRESSION because tumor volume increased by 922.9% between baseline (28.9 ml) and follow-up (295.2 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 99.8%."
Patient-065,week-000-2,week-102,28.85,119.59,90.74,314.5,Progression,Progression,PD,0.862,True,"Predicted PROGRESSION because tumor volume increased by 314.5% between baseline (28.9 ml) and follow-up (119.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 86.2%."
Patient-066,week-000,week-016,213.61,1.97,-211.64,-99.1,Non-Progression,Non-Progression,SD,0.657,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -99.1% (baseline: 213.6 ml → follow-up: 2.0 ml). This suggests treatment response. Confidence: 65.7%.
Patient-066,week-000,week-031,213.61,9.64,-203.97,-95.5,Non-Progression,Progression,PD,0.616,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -95.5% (baseline: 213.6 ml → follow-up: 9.6 ml). This suggests treatment response. Confidence: 61.6%.
Patient-066,week-000,week-046,213.61,13.74,-199.86,-93.6,Non-Progression,Progression,PD,0.563,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -93.6% (baseline: 213.6 ml → follow-up: 13.7 ml). This suggests treatment response. Confidence: 56.3%.
Patient-066,week-000,week-068,213.61,26.8,-186.81,-87.5,Non-Progression,Progression,PD,0.556,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.5% (baseline: 213.6 ml → follow-up: 26.8 ml). This suggests treatment response. Confidence: 55.6%.
Patient-066,week-000,week-084,213.61,65.17,-148.44,-69.5,Progression,Progression,PD,0.651,True,Predicted PROGRESSION despite apparent volume decrease of -69.5% (baseline: 213.6 ml → follow-up: 65.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 65.1%. Clinical review recommended.
Patient-066,week-000,week-101,213.61,40.08,-173.53,-81.2,Progression,Progression,PD,0.559,True,Predicted PROGRESSION despite apparent volume decrease of -81.2% (baseline: 213.6 ml → follow-up: 40.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 55.9%. Clinical review recommended.
Patient-067,week-000-1,week-013,3.95,28.1,24.15,611.0,Non-Progression,Progression,PD,0.542,False,Predicted NON-PROGRESSION despite volume increase of 611.0% (baseline: 4.0 ml → follow-up: 28.1 ml). Model suggests stability based on learned patterns. Confidence: 54.2%. Close monitoring advised.
Patient-067,week-000-1,week-033,3.95,32.34,28.39,718.1,Non-Progression,Progression,PD,0.513,False,Predicted NON-PROGRESSION despite volume increase of 718.1% (baseline: 4.0 ml → follow-up: 32.3 ml). Model suggests stability based on learned patterns. Confidence: 51.3%. Close monitoring advised.
Patient-067,week-000-1,week-042,3.95,13.2,9.24,233.8,Non-Progression,Progression,PD,0.624,False,Predicted NON-PROGRESSION despite volume increase of 233.8% (baseline: 4.0 ml → follow-up: 13.2 ml). Model suggests stability based on learned patterns. Confidence: 62.4%. Close monitoring advised.
Patient-067,week-000-1,week-053,3.95,15.3,11.35,287.0,Non-Progression,Progression,PD,0.62,False,Predicted NON-PROGRESSION despite volume increase of 287.0% (baseline: 4.0 ml → follow-up: 15.3 ml). Model suggests stability based on learned patterns. Confidence: 62.0%. Close monitoring advised.
Patient-067,week-000-1,week-068,3.95,30.17,26.22,663.2,Non-Progression,Non-Progression,SD,0.529,True,Predicted NON-PROGRESSION despite volume increase of 663.2% (baseline: 4.0 ml → follow-up: 30.2 ml). Model suggests stability based on learned patterns. Confidence: 52.9%. Close monitoring advised.
Patient-067,week-000-1,week-073,3.95,43.89,39.94,1010.4,Progression,Non-Progression,SD,0.557,False,"Predicted PROGRESSION because tumor volume increased by 1010.4% between baseline (4.0 ml) and follow-up (43.9 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 55.7%."
Patient-067,week-000-1,week-077,3.95,35.67,31.71,802.3,Progression,Non-Progression,SD,0.51,False,"Predicted PROGRESSION because tumor volume increased by 802.3% between baseline (4.0 ml) and follow-up (35.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 51.0%."
Patient-067,week-000-1,week-079,3.95,37.27,33.32,842.8,Progression,Non-Progression,SD,0.622,False,"Predicted PROGRESSION because tumor volume increased by 842.8% between baseline (4.0 ml) and follow-up (37.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 62.2%."
Patient-067,week-000-1,week-092,3.95,27.39,23.44,592.9,Progression,Non-Progression,SD,0.536,False,"Predicted PROGRESSION because tumor volume increased by 592.9% between baseline (4.0 ml) and follow-up (27.4 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 53.6%."
Patient-067,week-000-1,week-109,3.95,36.55,32.6,824.6,Progression,Progression,PD,0.532,True,"Predicted PROGRESSION because tumor volume increased by 824.6% between baseline (4.0 ml) and follow-up (36.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 53.2%."
Patient-067,week-000-1,week-124,3.95,36.73,32.78,829.2,Progression,Progression,PD,0.517,True,"Predicted PROGRESSION because tumor volume increased by 829.2% between baseline (4.0 ml) and follow-up (36.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 51.7%."
Patient-067,week-000-1,week-136,3.95,35.72,31.77,803.6,Progression,Progression,PD,0.506,True,"Predicted PROGRESSION because tumor volume increased by 803.6% between baseline (4.0 ml) and follow-up (35.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 50.6%."
Patient-067,week-000-1,week-152,3.95,93.72,89.77,2270.9,Progression,Progression,PD,0.815,True,"Predicted PROGRESSION because tumor volume increased by 2270.9% between baseline (4.0 ml) and follow-up (93.7 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 81.5%."
Patient-067,week-000-1,week-156,3.95,124.91,120.96,3059.9,Progression,Progression,PD,0.906,True,"Predicted PROGRESSION because tumor volume increased by 3059.9% between baseline (4.0 ml) and follow-up (124.9 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 90.6%."
Patient-067,week-000-1,week-167,3.95,143.62,139.66,3533.1,Progression,Progression,PD,0.939,True,"Predicted PROGRESSION because tumor volume increased by 3533.1% between baseline (4.0 ml) and follow-up (143.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 93.9%."
Patient-068,week-000-1,week-004,24.37,19.34,-5.03,-20.6,Non-Progression,Progression,PD,0.589,False,Predicted NON-PROGRESSION with tumor volume decrease of -20.6% (baseline: 24.4 ml → follow-up: 19.3 ml). Volume remains stable or reduced. Confidence: 58.9%.
Patient-068,week-000-1,week-010,24.37,9.15,-15.23,-62.5,Non-Progression,Non-Progression,PR,0.668,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -62.5% (baseline: 24.4 ml → follow-up: 9.1 ml). This suggests treatment response. Confidence: 66.8%.
Patient-068,week-000-1,week-022,24.37,4.55,-19.82,-81.3,Non-Progression,Non-Progression,PR,0.693,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -81.3% (baseline: 24.4 ml → follow-up: 4.6 ml). This suggests treatment response. Confidence: 69.3%.
Patient-068,week-000-1,week-035,24.37,43.34,18.97,77.8,Progression,Progression,PD,0.561,True,"Predicted PROGRESSION because tumor volume increased by 77.8% between baseline (24.4 ml) and follow-up (43.3 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 56.1%."
Patient-068,week-000-1,week-047,24.37,157.11,132.74,544.6,Progression,Progression,PD,0.95,True,"Predicted PROGRESSION because tumor volume increased by 544.6% between baseline (24.4 ml) and follow-up (157.1 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 95.0%."
Patient-071,week-000-1,week-024,203.04,42.04,-160.99,-79.3,Progression,Progression,PD,0.528,True,Predicted PROGRESSION despite apparent volume decrease of -79.3% (baseline: 203.0 ml → follow-up: 42.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 52.8%. Clinical review recommended.
Patient-071,week-000-1,week-027,203.04,42.97,-160.07,-78.8,Progression,Progression,PD,0.592,True,Predicted PROGRESSION despite apparent volume decrease of -78.8% (baseline: 203.0 ml → follow-up: 43.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 59.2%. Clinical review recommended.
Patient-071,week-000-1,week-052,203.04,74.16,-128.88,-63.5,Progression,Progression,PD,0.719,True,Predicted PROGRESSION despite apparent volume decrease of -63.5% (baseline: 203.0 ml → follow-up: 74.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 71.9%. Clinical review recommended.
Patient-071,week-000-1,week-058,203.04,120.13,-82.91,-40.8,Progression,Progression,PD,0.863,True,Predicted PROGRESSION despite apparent volume decrease of -40.8% (baseline: 203.0 ml → follow-up: 120.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 86.3%. Clinical review recommended.
Patient-071,week-000-1,week-062,203.04,83.72,-119.32,-58.8,Progression,Progression,PD,0.756,True,Predicted PROGRESSION despite apparent volume decrease of -58.8% (baseline: 203.0 ml → follow-up: 83.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 75.6%. Clinical review recommended.
Patient-072,week-000-1,week-013,87.63,20.27,-67.37,-76.9,Non-Progression,Non-Progression,SD,0.574,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -76.9% (baseline: 87.6 ml → follow-up: 20.3 ml). This suggests treatment response. Confidence: 57.4%.
Patient-072,week-000-1,week-021,87.63,44.06,-43.58,-49.7,Progression,Progression,PD,0.547,True,Predicted PROGRESSION despite apparent volume decrease of -49.7% (baseline: 87.6 ml → follow-up: 44.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 54.7%. Clinical review recommended.
Patient-072,week-000-1,week-029,87.63,58.5,-29.14,-33.2,Progression,Progression,PD,0.62,True,Predicted PROGRESSION despite apparent volume decrease of -33.2% (baseline: 87.6 ml → follow-up: 58.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 62.0%. Clinical review recommended.
Patient-072,week-000-1,week-037,87.63,55.05,-32.58,-37.2,Progression,Non-Progression,PR,0.63,False,Predicted PROGRESSION despite apparent volume decrease of -37.2% (baseline: 87.6 ml → follow-up: 55.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.0%. Clinical review recommended.
Patient-072,week-000-1,week-046,87.63,42.27,-45.36,-51.8,Progression,Progression,PD,0.534,True,Predicted PROGRESSION despite apparent volume decrease of -51.8% (baseline: 87.6 ml → follow-up: 42.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.4%. Clinical review recommended.
Patient-072,week-000-1,week-055,87.63,42.45,-45.18,-51.6,Progression,Progression,PD,0.532,True,Predicted PROGRESSION despite apparent volume decrease of -51.6% (baseline: 87.6 ml → follow-up: 42.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.2%. Clinical review recommended.
Patient-072,week-000-1,week-064,87.63,42.69,-44.95,-51.3,Progression,Progression,PD,0.539,True,Predicted PROGRESSION despite apparent volume decrease of -51.3% (baseline: 87.6 ml → follow-up: 42.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.9%. Clinical review recommended.
Patient-072,week-000-1,week-073,87.63,42.07,-45.57,-52.0,Progression,Progression,PD,0.53,True,Predicted PROGRESSION despite apparent volume decrease of -52.0% (baseline: 87.6 ml → follow-up: 42.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.0%. Clinical review recommended.
Patient-072,week-000-1,week-078,87.63,47.33,-40.3,-46.0,Progression,Progression,PD,0.559,True,Predicted PROGRESSION despite apparent volume decrease of -46.0% (baseline: 87.6 ml → follow-up: 47.3 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 55.9%. Clinical review recommended.
Patient-072,week-000-1,week-090,87.63,51.92,-35.71,-40.8,Progression,Progression,PD,0.581,True,Predicted PROGRESSION despite apparent volume decrease of -40.8% (baseline: 87.6 ml → follow-up: 51.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 58.1%. Clinical review recommended.
Patient-072,week-000-1,week-105,87.63,47.1,-40.53,-46.3,Progression,Progression,PD,0.579,True,Predicted PROGRESSION despite apparent volume decrease of -46.3% (baseline: 87.6 ml → follow-up: 47.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 57.9%. Clinical review recommended.
Patient-073,week-000,week-015,183.49,2.6,-180.89,-98.6,Non-Progression,Non-Progression,SD,0.701,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -98.6% (baseline: 183.5 ml → follow-up: 2.6 ml). This suggests treatment response. Confidence: 70.1%.
Patient-073,week-000,week-032,183.49,8.05,-175.44,-95.6,Non-Progression,Non-Progression,SD,0.67,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -95.6% (baseline: 183.5 ml → follow-up: 8.1 ml). This suggests treatment response. Confidence: 67.0%.
Patient-073,week-000,week-046,183.49,17.69,-165.8,-90.4,Non-Progression,Non-Progression,SD,0.579,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -90.4% (baseline: 183.5 ml → follow-up: 17.7 ml). This suggests treatment response. Confidence: 57.9%.
Patient-073,week-000,week-060,183.49,19.52,-163.97,-89.4,Non-Progression,Non-Progression,SD,0.569,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -89.4% (baseline: 183.5 ml → follow-up: 19.5 ml). This suggests treatment response. Confidence: 56.9%.
Patient-073,week-000,week-087,183.49,24.56,-158.94,-86.6,Non-Progression,Progression,PD,0.568,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -86.6% (baseline: 183.5 ml → follow-up: 24.6 ml). This suggests treatment response. Confidence: 56.8%.
Patient-073,week-000,week-100,183.49,22.27,-161.22,-87.9,Non-Progression,Progression,PD,0.583,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.9% (baseline: 183.5 ml → follow-up: 22.3 ml). This suggests treatment response. Confidence: 58.3%.
Patient-073,week-000,week-119,183.49,31.7,-151.79,-82.7,Progression,Progression,PD,0.521,True,Predicted PROGRESSION despite apparent volume decrease of -82.7% (baseline: 183.5 ml → follow-up: 31.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 52.1%. Clinical review recommended.
Patient-073,week-000,week-135,183.49,37.58,-145.91,-79.5,Progression,Non-Progression,SD,0.549,False,Predicted PROGRESSION despite apparent volume decrease of -79.5% (baseline: 183.5 ml → follow-up: 37.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 54.9%. Clinical review recommended.
Patient-073,week-000,week-155,183.49,34.04,-149.45,-81.4,Progression,Non-Progression,SD,0.515,False,Predicted PROGRESSION despite apparent volume decrease of -81.4% (baseline: 183.5 ml → follow-up: 34.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.5%. Clinical review recommended.
Patient-073,week-000,week-169,183.49,37.9,-145.59,-79.3,Progression,Non-Progression,SD,0.551,False,Predicted PROGRESSION despite apparent volume decrease of -79.3% (baseline: 183.5 ml → follow-up: 37.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 55.1%. Clinical review recommended.
Patient-073,week-000,week-186,183.49,53.51,-129.98,-70.8,Progression,Non-Progression,SD,0.624,False,Predicted PROGRESSION despite apparent volume decrease of -70.8% (baseline: 183.5 ml → follow-up: 53.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 62.4%. Clinical review recommended.
Patient-073,week-000,week-202,183.49,48.69,-134.8,-73.5,Progression,Non-Progression,SD,0.602,False,Predicted PROGRESSION despite apparent volume decrease of -73.5% (baseline: 183.5 ml → follow-up: 48.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.2%. Clinical review recommended.
Patient-073,week-000,week-216,183.49,64.63,-118.87,-64.8,Progression,Progression,PD,0.674,True,Predicted PROGRESSION despite apparent volume decrease of -64.8% (baseline: 183.5 ml → follow-up: 64.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 67.4%. Clinical review recommended.
Patient-073,week-000,week-228,183.49,63.03,-120.46,-65.6,Progression,Progression,PD,0.677,True,Predicted PROGRESSION despite apparent volume decrease of -65.6% (baseline: 183.5 ml → follow-up: 63.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 67.7%. Clinical review recommended.
Patient-073,week-000,week-242,183.49,68.51,-114.98,-62.7,Progression,Progression,PD,0.69,True,Predicted PROGRESSION despite apparent volume decrease of -62.7% (baseline: 183.5 ml → follow-up: 68.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 69.0%. Clinical review recommended.
Patient-074,week-000-2,week-026,27.68,18.84,-8.84,-31.9,Non-Progression,Progression,PD,0.614,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -31.9% (baseline: 27.7 ml → follow-up: 18.8 ml). This suggests treatment response. Confidence: 61.4%.
Patient-074,week-000-2,week-039,27.68,22.49,-5.19,-18.8,Non-Progression,Progression,PD,0.572,False,Predicted NON-PROGRESSION with tumor volume decrease of -18.8% (baseline: 27.7 ml → follow-up: 22.5 ml). Volume remains stable or reduced. Confidence: 57.2%.
Patient-075,week-000,week-020,16.44,6.49,-9.95,-60.5,Non-Progression,Non-Progression,SD,0.683,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -60.5% (baseline: 16.4 ml → follow-up: 6.5 ml). This suggests treatment response. Confidence: 68.3%.
Patient-075,week-000,week-032,16.44,61.62,45.18,274.8,Progression,Progression,PD,0.632,True,"Predicted PROGRESSION because tumor volume increased by 274.8% between baseline (16.4 ml) and follow-up (61.6 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 63.2%."
Patient-075,week-000,week-044,16.44,35.53,19.09,116.1,Progression,Non-Progression,PR,0.513,False,"Predicted PROGRESSION because tumor volume increased by 116.1% between baseline (16.4 ml) and follow-up (35.5 ml), exceeding the 25% volume-change heuristic inspired by RANO progression criteria. Model confidence: 51.3%."
Patient-077,week-000,week-014,164.97,5.44,-159.53,-96.7,Non-Progression,Non-Progression,SD,0.624,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -96.7% (baseline: 165.0 ml → follow-up: 5.4 ml). This suggests treatment response. Confidence: 62.4%.
Patient-077,week-000,week-026,164.97,19.66,-145.31,-88.1,Non-Progression,Progression,PD,0.595,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -88.1% (baseline: 165.0 ml → follow-up: 19.7 ml). This suggests treatment response. Confidence: 59.5%.
Patient-077,week-000,week-048,164.97,31.5,-133.47,-80.9,Non-Progression,Progression,PD,0.505,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -80.9% (baseline: 165.0 ml → follow-up: 31.5 ml). This suggests treatment response. Confidence: 50.5%.
Patient-077,week-000,week-062,164.97,48.83,-116.14,-70.4,Progression,Progression,PD,0.609,True,Predicted PROGRESSION despite apparent volume decrease of -70.4% (baseline: 165.0 ml → follow-up: 48.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.9%. Clinical review recommended.
Patient-077,week-000,week-070,164.97,38.08,-126.89,-76.9,Progression,Progression,PD,0.521,True,Predicted PROGRESSION despite apparent volume decrease of -76.9% (baseline: 165.0 ml → follow-up: 38.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 52.1%. Clinical review recommended.
Patient-077,week-000,week-083,164.97,86.06,-78.91,-47.8,Progression,Progression,PD,0.779,True,Predicted PROGRESSION despite apparent volume decrease of -47.8% (baseline: 165.0 ml → follow-up: 86.1 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 77.9%. Clinical review recommended.
Patient-078,week-000,week-005,114.03,13.88,-100.15,-87.8,Non-Progression,Non-Progression,SD,0.599,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -87.8% (baseline: 114.0 ml → follow-up: 13.9 ml). This suggests treatment response. Confidence: 59.9%.
Patient-078,week-000,week-019,114.03,51.84,-62.19,-54.5,Progression,Non-Progression,SD,0.599,False,Predicted PROGRESSION despite apparent volume decrease of -54.5% (baseline: 114.0 ml → follow-up: 51.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 59.9%. Clinical review recommended.
Patient-078,week-000,week-029,114.03,59.6,-54.43,-47.7,Progression,Progression,PD,0.657,True,Predicted PROGRESSION despite apparent volume decrease of -47.7% (baseline: 114.0 ml → follow-up: 59.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 65.7%. Clinical review recommended.
Patient-078,week-000,week-037,114.03,64.17,-49.86,-43.7,Progression,Progression,PD,0.647,True,Predicted PROGRESSION despite apparent volume decrease of -43.7% (baseline: 114.0 ml → follow-up: 64.2 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 64.7%. Clinical review recommended.
Patient-078,week-000,week-039,114.03,50.87,-63.16,-55.4,Progression,Progression,PD,0.603,True,Predicted PROGRESSION despite apparent volume decrease of -55.4% (baseline: 114.0 ml → follow-up: 50.9 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.3%. Clinical review recommended.
Patient-078,week-000,week-041,114.03,36.04,-77.99,-68.4,Progression,Progression,PD,0.521,True,Predicted PROGRESSION despite apparent volume decrease of -68.4% (baseline: 114.0 ml → follow-up: 36.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 52.1%. Clinical review recommended.
Patient-078,week-000,week-045,114.03,26.29,-87.73,-76.9,Non-Progression,Progression,PD,0.534,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -76.9% (baseline: 114.0 ml → follow-up: 26.3 ml). This suggests treatment response. Confidence: 53.4%.
Patient-078,week-000,week-056,114.03,24.62,-89.4,-78.4,Non-Progression,Progression,PD,0.569,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -78.4% (baseline: 114.0 ml → follow-up: 24.6 ml). This suggests treatment response. Confidence: 56.9%.
Patient-078,week-000,week-062,114.03,30.4,-83.62,-73.3,Non-Progression,Progression,PD,0.531,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -73.3% (baseline: 114.0 ml → follow-up: 30.4 ml). This suggests treatment response. Confidence: 53.1%.
Patient-078,week-000,week-076,114.03,34.39,-79.64,-69.8,Progression,Progression,PD,0.512,True,Predicted PROGRESSION despite apparent volume decrease of -69.8% (baseline: 114.0 ml → follow-up: 34.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.2%. Clinical review recommended.
Patient-078,week-000,week-088,114.03,35.67,-78.36,-68.7,Progression,Progression,PD,0.512,True,Predicted PROGRESSION despite apparent volume decrease of -68.7% (baseline: 114.0 ml → follow-up: 35.7 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.2%. Clinical review recommended.
Patient-078,week-000,week-106,114.03,40.44,-73.59,-64.5,Progression,Non-Progression,PR,0.536,False,Predicted PROGRESSION despite apparent volume decrease of -64.5% (baseline: 114.0 ml → follow-up: 40.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.6%. Clinical review recommended.
Patient-078,week-000,week-113,114.03,39.53,-74.5,-65.3,Progression,Progression,PD,0.541,True,Predicted PROGRESSION despite apparent volume decrease of -65.3% (baseline: 114.0 ml → follow-up: 39.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 54.1%. Clinical review recommended.
Patient-078,week-000,week-116,114.03,40.79,-73.24,-64.2,Progression,Progression,PD,0.535,True,Predicted PROGRESSION despite apparent volume decrease of -64.2% (baseline: 114.0 ml → follow-up: 40.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 53.5%. Clinical review recommended.
Patient-078,week-000,week-119,114.03,55.97,-58.06,-50.9,Progression,Progression,PD,0.635,True,Predicted PROGRESSION despite apparent volume decrease of -50.9% (baseline: 114.0 ml → follow-up: 56.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.5%. Clinical review recommended.
Patient-080,week-000,week-018,66.91,19.05,-47.86,-71.5,Non-Progression,Non-Progression,SD,0.587,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -71.5% (baseline: 66.9 ml → follow-up: 19.1 ml). This suggests treatment response. Confidence: 58.7%.
Patient-081,week-000-1,week-006,89.54,35.79,-53.74,-60.0,Progression,Progression,PD,0.511,True,Predicted PROGRESSION despite apparent volume decrease of -60.0% (baseline: 89.5 ml → follow-up: 35.8 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 51.1%. Clinical review recommended.
Patient-082,week-000-1,week-003,182.65,8.6,-174.05,-95.3,Non-Progression,Non-Progression,SD,0.602,True,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -95.3% (baseline: 182.7 ml → follow-up: 8.6 ml). This suggests treatment response. Confidence: 60.2%.
Patient-084,week-000-2,week-012,101.05,77.36,-23.69,-23.4,Progression,Non-Progression,SD,0.728,False,Predicted PROGRESSION despite apparent volume decrease of -23.4% (baseline: 101.0 ml → follow-up: 77.4 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 72.8%. Clinical review recommended.
Patient-085,week-000-2,week-018,72.7,63.48,-9.22,-12.7,Progression,Progression,PD,0.63,True,Predicted PROGRESSION despite apparent volume decrease of -12.7% (baseline: 72.7 ml → follow-up: 63.5 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 63.0%. Clinical review recommended.
Patient-085,week-000-2,week-042,72.7,55.05,-17.66,-24.3,Progression,Progression,PD,0.609,True,Predicted PROGRESSION despite apparent volume decrease of -24.3% (baseline: 72.7 ml → follow-up: 55.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 60.9%. Clinical review recommended.
Patient-085,week-000-2,week-050,72.7,76.96,4.26,5.9,Progression,Progression,PD,0.753,True,"Predicted PROGRESSION with tumor volume increase of 5.9% (baseline: 72.7 ml → follow-up: 77.0 ml). Although below the 25% heuristic threshold, the model identified progression patterns. Confidence: 75.3%."
Patient-086,week-000,week-173-1,169.4,93.98,-75.42,-44.5,Progression,Progression,PD,0.779,True,Predicted PROGRESSION despite apparent volume decrease of -44.5% (baseline: 169.4 ml → follow-up: 94.0 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 77.9%. Clinical review recommended.
Patient-086,week-000,week-181,169.4,130.6,-38.8,-22.9,Progression,Progression,PD,0.88,True,Predicted PROGRESSION despite apparent volume decrease of -22.9% (baseline: 169.4 ml → follow-up: 130.6 ml). This may indicate non-enhancing progression or measurement variability. Confidence: 88.0%. Clinical review recommended.
Patient-087,week-000-1,week-024,23.01,7.61,-15.4,-66.9,Non-Progression,Progression,PD,0.655,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -66.9% (baseline: 23.0 ml → follow-up: 7.6 ml). This suggests treatment response. Confidence: 65.5%.
Patient-089,week-000-1,week-045,141.16,32.24,-108.92,-77.2,Non-Progression,Progression,PD,0.518,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -77.2% (baseline: 141.2 ml → follow-up: 32.2 ml). This suggests treatment response. Confidence: 51.8%.
Patient-089,week-000-1,week-056,141.16,12.45,-128.72,-91.2,Non-Progression,Progression,PD,0.59,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -91.2% (baseline: 141.2 ml → follow-up: 12.4 ml). This suggests treatment response. Confidence: 59.0%.
Patient-089,week-000-1,week-064,141.16,21.83,-119.34,-84.5,Non-Progression,Progression,PD,0.586,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -84.5% (baseline: 141.2 ml → follow-up: 21.8 ml). This suggests treatment response. Confidence: 58.6%.
Patient-090,week-000-1,week-029,18.39,15.0,-3.39,-18.5,Non-Progression,Progression,PD,0.612,False,Predicted NON-PROGRESSION with tumor volume decrease of -18.5% (baseline: 18.4 ml → follow-up: 15.0 ml). Volume remains stable or reduced. Confidence: 61.2%.
Patient-091,week-000,week-014,50.65,17.66,-32.99,-65.1,Non-Progression,Progression,PD,0.615,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -65.1% (baseline: 50.6 ml → follow-up: 17.7 ml). This suggests treatment response. Confidence: 61.5%.
Patient-091,week-000,week-026,50.65,21.93,-28.72,-56.7,Non-Progression,Progression,PD,0.579,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -56.7% (baseline: 50.6 ml → follow-up: 21.9 ml). This suggests treatment response. Confidence: 57.9%.
Patient-091,week-000,week-036,50.65,21.84,-28.81,-56.9,Non-Progression,Progression,PD,0.587,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -56.9% (baseline: 50.6 ml → follow-up: 21.8 ml). This suggests treatment response. Confidence: 58.7%.
Patient-091,week-000,week-043,50.65,21.24,-29.41,-58.1,Non-Progression,Progression,PD,0.591,False,Predicted NON-PROGRESSION (likely response) with significant tumor volume decrease of -58.1% (baseline: 50.6 ml → follow-up: 21.2 ml). This suggests treatment response. Confidence: 59.1%.
